Literatur
Aarnink RG, de la Rosette JJ, Debruyne FM, Wijkstra H (1996) Formula-derived prostate volume determination. Eur Urol 29: 399–402
Aarnink RG, de la Rosette JJ, Debruyne FM, Wijkstra H (1996) Reproducibility of prostate volume measurements from transrectal ultrasonography by an automated and a manual technique. B J Urol 78: 219–223
Abrams P (1995) Objective evaluation of bladder outlet obstruction. Br J Urol 76: 11–15
Ameda K, Koyanagi T, Nantani M, Taniguchi K, Matsuno T (1994) The relevance of preoperative cystometrography in patients with benign prostatic hyperplasia: correlating the findings with clinical features and outcome after prostatectomy. J Urol 152: 443–447
Anderson JR, Strickland D, Corbin D, Byrnes JA, Zweiback E (1995) Age-specific reference ranges for serum prostate-specific antigen. Urology 46: 54–57
Anyanwu SNC (1995) Is routine urography necessary in all patients undergoing suprapubic transvesical prostatectomy? East Afr Med J 72/2: 78
Barry MJ, Cockett AT, Holtgrewe HL et al. (1993) Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150: 351–358
Bergdahl S, Aus G, Lodding P, Norlen L, Hugosson J (1999) Transrectal ultrasound with separate measurement of the transition zone predicts the short-term outcome after transurethral resection of the prostate. Urology 53: 926–930
Bosch JL (1995) Postvoid residual urine in the evaluation of men with benign prostatic hyperplasia. World J Urol 13: 17–20
Bosch JL, Hop WC, Kirkels WJ, Schröder FH (1995) The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 75: 622–630
Bruskewitz RC, Iversen P, Madsen PO (1982) Value of postvoided residual urine determination in evaluation of prostatism. Urology 20: 602–604
Chandiramani VA, Palace J, Fowler CJ (1997) How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 80: 100–104
Chapple CR, Smith D (1994) The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol 73: 117–121
Comiter CV, Sullivan MP, Schacterle RS, Cohen LH, Valla SV (1997) Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. J Urol 158: 181–185
De la Rosette JJ, Witjes WP, Debruyne FM, Kerstein PL, Wijkstra H (1996) Improved reliability of uroflowmetry investigations: results of a portable home-based uroflowmetry study. Br J Urol 78: 385–390
Diokno AC (1996) Editorial: the impact of technological and scientific advances in understanding, evaluating and managing bladder and outlet obstruction. J Urol 155: 527–158
Dörsam J, Kälble T, Riedasch G, Staehler G (1994) Wertigkeit der bildgebenden Diagnostik bei benigner Prostatahyperplasie und beim Prostatakarzinom. Radiologe 34: 101–108
DuBeau CE, Sullivan MP, Cravalho E, Resnick NM, Yalla SV (1995) Correlation between micturitional urethral pressure profile and pressure-flow criteria in bladder outlet obstruction. J Urol 154: 498–503
Dunsmuir WD, Feneley M, Corry DA, Bryan CJ, Kirby RS (1996) The day-to-day variation (test-retest reliability) of residual urine measurement. Br J Urol 77 2:192–193
El Din K, Koch WF, de Wildt MJ, Debruyne FM, de la Rosette JJ (1996) The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Eur Urol 30: 409–413
El Din KE, Kiemeney LA, de Wildt MJ, Debruyne FM, de La Rosette JJ (1996) Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the international prostate symptom score. Urology 48: 393–397
Fall M, Geirsson G, Lindstrom S (1995) Towards a new classification of overactive bladders. Neurourol Urodyn 14/6: 635–646
Feneley MR, Dunsmuir WD, Pearce J, Kirby RS (1996) Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia. Urology 47/5: 658–663
Gerber GS (1996) The role of urodynamic study in the evaluation and management of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 48: 668–675
Gleason DM, Bottaccini MR, McRae LP (1997) Noninvasive urodynamics: a study of male voiding dysfunction. Neurourol Urodyn 16: 93–100
Goessl C, Knispel HH, Miller K, Klan R (1997) Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 157: 480–481
Goldenberg S, Gleave M, Bruchovsky N, Rennie P (1997) The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis—Editorial Comment. J Urol 157: 2267
Griffiths D (1995) Basics of pressure-flow studies. World J Urol 13: 30–33
Griffiths D, Harrison G, Moore K, McCracken P (1994) Long-term changes in urodynamics studies of voiding in the elderly. Urol Res 22: 235–238
Griffiths K, Coffey D, Cockett A et al. (1996) The regulation of prostatic growth. In: Cockett ATK, Khoury S, Aso Y et al. (eds) The 3rd International Consultation on Benign Prostatic Hyerplasia (BPH). Scientific Communication International, Monaco, pp 73–121
Griffiths D, Höfner K, van Mastrigt R et al. (1997) Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. Neurourol Urodyn 16: 1-18
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49: 749–754
Hall MC, Roehrborn CG, McConnell JD (1996) Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia? Seminars in Urologic Oncology 14: 122–133
Hampson SJ, Noble JG, Richards D, Milroy EJG (1992) Does residual urine predispose to urinary tract infection? Br J Urol 70: 506–508
Harzmann R, Weckermann D (1995) Diagnostik und Therapie des Prostataadenoms—Bewährtes und Neues. Med Welt 46: 454–457
Hasegawa Y, Sakamoto N, Gotoh K (1996) Relationship of ultrasonic and histologic findings in benign prostatic hyperplasia. Prostate 28/2: 111-116
Höfner K, Kramer EJ, Tan HK, Krah H, Jonas U (1995) CHESS classification of bladder-outflow obstruction. A consequence in the discussion of current concepts. World Journal of Urology 13: 59–64
Jacobsen SJ (1995) Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology 45: 64–69
Janknegt RA, Roehrborn CG (1994) The role of the general practitioner in the diagnosis and treatment of benign prostatic hyperplasia (BPH). Prog Clin Biol Res 386: 313–329
Javle P, Jenkins SA, West C, Parsons KE (1996) Quantification of voiding dysfunction in patients awaiting transurethral prostatectomy. J Urol 156: 1014–1019
Jensen KM, Jorgensen JB, Morgensen P (1996) Long-term predictive role of urodynamics: an 8-year follow-up of prostatic surgery for lower urinary tract symptoms. Br J Urol 78/27: 213–218
Jonas U, Kramer G, Hofner K (1994) The principles and clinical application of advanced urodynamic analysis for BPH. Prog Clin Biol Res 386: 141–156
Jonas U, Höfner K (1996) Symptom scores, watchful waiting and prostate specific antigen levels in benign prostatic hyperplasia—Editorial. J Urol 156: 1040–1041
Jorgensen JB, Jensen KM (1996) Uroflowmetry. Urol Clin North Am 23/2: 237–242
Kaplan SA, Te AE (1995) Uroflowmetry and urodynamics. Urol Clin North Am 22: 309–320
Kaplan SA, Reis RB (1996) Significant correlation of the American Urological Association symptom score and a novel urodynamic parameter: Detrusor contraction duration. J Urol 156: 1668–1672
Koch WF, Ezzeldin K, de Wildt MJ, Debruyne FM, de la Rosette JJ (1996) The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol 155: 186–189
Kojima M, Inui E, Ochiai A et al. (1997) Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol 157: 476–479
Kurita Y, Masuda H, Terada H, Suzuki K, Fujita K (1998) Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology 51: 595–600
Lim CS, Abrams P (1995) The Abrams-Griffiths Nomogram. World J Urol 13: 34–39
Madersbacher S, Klingler HC, Diavan B et al. (1997) Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms? Br J Urol 80: 72–77
Madsen FA, Bruskewitz RC (1995) Cystoscopy in the evaluation of benign prostatic hyperplasia. World J Urol 13: 14–16
Manieri C, Carter SS, Romano G et al. (1998) The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J Urol 159: 761–765
McConnell JD (1994) Why pressure-flow studies should be optional and not mandatory studies for evaluating men with benign prostatic hyperplasia. Urology 44: 156–158
McGuire E (1996) Editorial comment—Combinations of maximum urinary flow rate and American Urological Association symptom index that are more specific for identifying obstructive and non-obstructive prostatism. Neurourol Urodyn 15: 470–471
Nathan MS, Seenivasagam K, Mei Q, Wickham JE, Miller RA (1996) Transrectal ultrasonography: why are estimates of prostate volume and dimension so inaccurate? Br J Urol 77: 401–407
Netto NR, D'Ancona CAL, Lopes de Lima M (1996) Correlation between the International Prostatic Symptom Score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia. J Urol 155: 200–202
Oelke M, Höfner K, Jonas U (2000) Standardisierung der sonographischen Detrusordickenmessung. Urologe A 39 (Suppl. 1): 136
Oelke M, Höfner K, Wiese B, Grünewald V, Jonas U (2002) Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol 19: 443–452
Oesterling JE, Girman CJ, Panser LA et al. (1994) Correlation between urinary flow rate, voided volume, and patient age in a community-based population. Prog Clin Biol Res 386: 125–139
Othani T, Hayashi Y, Kishino TE et al. (1999) A new parameter in decision making for transurethral electroresection of benign prostatic hyperplasia. Eur Urol 35: 185–191
Reynard JM, Peters TJ, Lim C, Abrams P (1996) The value of multiple free-flow studies in men with lower urinary tract symptoms. Br J Urol 77: 813–818
Reynard JM, Yang Q, Donovan JL et al. (1998) The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 82: 619–623
Roehrborn CG, Girman CJ, Rhodes T et al. (1997) Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 49: 548–557
Rosier PF, de la Rosette JJ (1995) Is there a correlation between prostata size and bladder-outlet obstruction? World J Urol 13: 9-13
Ruud Bosch JL (1995) Postvoid residual urine in the evaluation of men with benign prostatic hyperplasia. World J Urol 13: 17–20
Schacterle RS, Sullivan MP, Yalla SV (1996) Reply—Combinations of maximum urinary flow rate and American Urological Association symptom index that are more specific for identifying obstructive and non-obstructive prostatism. Neurourol Urodyn 15: 471–472
Schäfer W, de la Rosette JJ, Höfner K et al. (1994) The ICS BPH study: pressure-flow studies, quality control and initial analysis. Neurourol Urodyn 13: 491–492
Schleicher C, Neumann R, Kaiser WA, Stein G (1997) Zur Indikation der intravenösen Urographie. Med Klin 92: 79–82
Sullivan MP, Comiter CV, Yalla SV (1996) Micturitional urethral pressure profilometry. Urol Clin North Am 23/2: 263–278
Ukimura O, Kojima M, Inui E et al. (1996) A statistical study of the American Urological Association symptom index for benign prostatic hyperplasia in participants of mass screening program for prostatic diseases using transrectal sonography. J Urol 156: 1673–1678
van de Beek C, Stoevelaar HJ, McDonnell J et al. (1997) Interpretation of uroflowmetry curves by urologists. J Urol 157: 164–168
van Venrooij GE, Boon TA (1996) The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. J Urol 155/6: 2014–2018
Walsh PC (1984) Human benign prostatic hyperplasia: etiological considerations. In: Kimball FA et al. (eds) New approaches to the study of benign prostatic hyperplasia. Alan R Liss, New York, pp 1–25
Witjes WP, de Wildt MJ, Rosier PF et al. (1996) Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol 156: 1026–1033
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Einstufung der Leitlinie nach AWMF: Stufe 2
Für den Arbeitskreis Urologische Funktionsdiagnostik u. Urologie der Frau: H. Palmtag, M. Goepel
Für den BDU: K. Schalkhäuser
Für die DGU-Leitlinienkommission: B. Göckel-Beining, A. Heidenreich, H. Rübben, K. Schalkhäuser, W. Thon, J. Thüroff, W. Weidner (Vorsitzender)
Stand: Februar 2003
Anhang
Anhang
Grundlage der Evidenzbewertung für Leitlinienempfehlungen:
Evidenzstufe
-
1.
Unterstützende Evidenz aus gut durchgeführten randomisierten, kontrollierten Studien mit 100 oder mehr Patienten.
-
Evidenz aus gut durchgeführten multizentrischen Studien.
-
Evidenz aus Metaanalysen, die Qualitätsränge in der Analyse berücksichtigen und insgesamt mindestens 100 Patienten für die Berechnung von Effektgröße und Konfidenzintervall berücksichtigen.
-
-
2.
Unterstützende Evidenz aus gut durchgeführten randomisierten, kontrollierten Studien mit weniger als 100 Patienten.
-
Evidenz aus gut durchgeführten Studien aus einem oder mehreren Zentren.
-
Evidenz aus Metaanalysen, die Qualitätsränge in der Analyse berücksichtigen und weniger als 100 Patienten für die Berechnung von Effektgröße und Konfidenzintervall berücksichtigen.
-
-
3.
Unterstützende Evidenz aus gut durchgeführten Kohortenstudien.
-
Evidenz aus gut durchgeführter prospektiver Kohortenstudie.
-
Evidenz aus gut durchgeführter retrospektiver Kohortenstudie.
-
Evidenz aus gut durchgeführter Metaanalyse aus Kohortenstudien.
-
-
4.
Unterstützende Evidenz aus gut durchgeführten Fallkontrollstudien.
-
5.
Unterstützende Evidenz aus schlecht kontrollierten oder unkontrollierten Studien.
-
Evidenz aus randomisierten klinischen Studien mit methodischen Fehlern.
-
Evidenz aus Anwendungsbeobachtungen mit hohem Beeinflussungspotential.
-
Evidenz aus Fallserien oder Fallberichten.
-
-
6.
Widersprüchliche Evidenz, die eine Empfehlung in Richtung der Evidenzlage unterstützt.
-
7.
Expertenmeinungen.
Zusammenfassende Graduierung:
-
Grad A: Evidenz aus 1–3.
-
Grad B: Evidenz aus 4–5.
-
Grad C: Evidenz aus 6–7.
Für die Leitlinien wurde alle Evidenzen mit Grad A berücksichtigt, zum Teil ergänzt durch unterstützende Evidenzen aus Grad B (soweit eine Grad-A-Evidenz nicht vorhanden ist). Nicht berücksichtigt wurde Evidenzen aus Grad C.
Rights and permissions
About this article
Cite this article
Oelke, M., R. Berges, K. Dreikorn, K. Höfner, U. Jonas (Vorsitzender), K. U. Laval, S. Madersbacher, M. C. Michel, R. Muschter, M. Oelke, L. Pientka, C. Tschuschke, U. Tunn für den Arbeitskreis BPH der Deutschen Gesellschaft für Urologie. Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe 42, 584–590 (2003). https://doi.org/10.1007/s00120-003-0319-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-003-0319-2